
Opinion|Videos|May 16, 2025
Strategies to Minimize Toxicities, and the Pharmacist’s Role in Educating and Supporting Patients With NSCLC
Author(s)Lauren Ledbetter, PharmD, BCOP
A panelist discusses how to minimize EGFR tyrosine kinase inhibitor (TKI) adverse effects through preventive measures such as maintaining good skin regimens with moisturizers and SPF 30+ sunscreen, prescribing topical steroids and antibiotics for skin rash, and managing diarrhea with hydration, diet modifications, and loperamide.
Advertisement
Episodes in this series

Management Strategies for EGFR TKI Adverse Effects: Summary for Physicians
Dermatologic Toxicity Management
- Proactive skin care regimen before initiating EGFR TKIs:
- Recommend non–alcohol-based creamy moisturizers (morning and night)
- Daily SPF 30+ sunscreen on exposed areas
- Encourage protective clothing (hats, long sleeves)
- Treatment options for acneiform rash:
- Topical steroids
- Topical clindamycin gel
- Oral doxycycline (helps reduce severity and prevent superimposed infection)
- Consider dermatology referral for severe cases
Diarrhea Management
- Patient education:
- Instruct patients to monitor and track stool frequency above baseline
- Emphasize adequate hydration
- Dietary modifications:
- Recommend BRAT-style diet (bananas, rice, apples, toast)
- Low-fiber, bland foods
- Avoid dairy, greasy, and fatty foods
- Pharmacologic intervention:
- Provide step-by-step loperamide (Imodium) dosing instructions
- Review medication list for potential exacerbating agents
- Instruct patients to hold laxatives/stool softeners during diarrhea episodes
Clinical Pearls
- Male patients may require additional encouragement regarding skin care regimens
- Emphasize importance of patient communication between visits
- Always perform medication reconciliation to identify potential contributory medications
- Ensure patients have clear instructions for all prescribed treatments
This approach focuses on proactive management to minimize adverse events while maintaining treatment efficacy.
Advertisement
Related to this article

An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.

Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.

Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.

A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.

Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.

A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.

IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
Tec-Dara Cuts Death Risk 78% Without Raising Fatal Toxicity
5


